US Health Department Cancels mRNA Vaccine Development Contracts Worth $500 Million

The US Department of Health and Human Services has made a significant shift in its vaccine development strategy, deciding to cancel contracts and cease funding for mRNA vaccine development activities aimed at combating respiratory viruses like flu and COVID-19. As part of this decision, 22 mRNA vaccine development investments, led by leading pharmaceutical companies such as Pfizer and Moderna, will be terminated. The biomedical research unit affected by the decision, the Biomedical Advanced Research and Development Authority (BARDA), has provided billions of dollars in funding for vaccine development during the COVID-19 pandemic.

Key Takeaways:

The US Department of Health and Human Services has canceled contracts worth $500 million for mRNA vaccine development activities to combat respiratory viruses like flu and COVID-19.
The Biomedical Advanced Research and Development Authority (BARDA) is terminating 22 mRNA vaccine development investments, including those led by Pfizer and Moderna.
These mRNA vaccines were credited with slowing down the coronavirus pandemic in 2020.
The health department is shifting funding toward "safer, broader vaccine platforms that remain effective even as viruses mutate."
Multiple pre-award solicitations, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others, have been canceled.

Statistics:

$500 million: The total worth of mRNA vaccine development contracts canceled by the US Department of Health and Human Services.
22: The number of mRNA vaccine development investments being terminated by BARDA.
$500 million: The amount of funding shifted toward safer, broader vaccine platforms by the health department.
2020: The year mRNA vaccines slowed down the coronavirus pandemic.

Sources:

"US Health Secretary Robert F. Kennedy Jr. (@SecKennedy) tweet on August 5, 2025
"IE Online Media Services Pvt. Ltd., distributed by Contify.com (2025)